Net patient service revenues totaled $433,247 for the three months ended December 31, 1999 versus $ 1,144,529 for the three months ended December 31, 1998. Cost of patient service operations totaled $273,371 for the three months ended December 31,1999 versus $970,675 for the three months ended December 31, 1998. The decreases from 1998 to 1999 are primarily due to the sale of the Aurora Technology and the rehabilitation business, partially offset by the additional net patient revenues and operating expenses for the Strax Institute.
Net product sales revenues for the three months ended December 31, 1999 totaled $473,812. The cost of goods for the Opus business for this period was $201,967 and is included in cost of operations. The Company acquired Opus' therapeutic drug monitoring products in June 1999.
Selling, general and administrative expenses totaled $665,172 for the three months ended December 31, 1999 versus $869,398 for the three months ended December 31, 1998. This decrease reflects the sale of Aurora Technology and the rehabilitation business as well as a shift in business focus to the Opus Diagnostics product line of therapeutic drug monitoring assays (TDM).
In 1998, research and development reflects the change in the accounting treatment of AMS from equity to consolidation accounting.
